bevasiranib

DRUG5 trials

Sponsors

OPKO Health, Inc.

Conditions

Age Related Macular DegenerationDiabetic Macular EdemaMacular Degeneration

Phase 1

Open Label Study for the Evaluation of Tolerability of Five Dose Levels of Cand5

CompletedNCT00722384

OPKO Health, Inc.Macular Degeneration

Start: 2004-08-31End: 2007-12-31Updated: 2008-07-25

Phase 2

Safety and Efficacy Study of Small Interfering Ribonucleic Acid (RNA) Molecule (Cand5) to Treat Wet Age-Related Macular Degeneration

CompletedNCT00259753

OPKO Health, Inc.Macular Degeneration

Start: 2005-07-31End: 2007-12-31Updated: 2008-08-05

Safety and Efficacy Study of Small Interfering RNA Molecule (Cand5) to Treat Diabetic Macular Edema

CompletedNCT00306904

OPKO Health, Inc.Diabetic Macular Edema

Start: 2006-01-31End: 2007-12-31Updated: 2008-07-25

Phase 3

Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD

TerminatedNCT00499590

OPKO Health, Inc.Macular Degeneration

Start: 2007-08-31End: 2009-05-31Updated: 2014-10-06

Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (CARBON)

WithdrawnNCT00557791

OPKO Health, Inc.Age Related Macular Degeneration

Start: 2009-11-30End: 2012-07-31Updated: 2015-03-06